Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Futura Medical plc (FAMDF)
Guildford, GB
Futura Medical plc is a pharmaceutical company that formulates and brings to market healthcare solutions and medicines for the consumer sector, primarily concentrating on sexual well-being and managing discomfort. Their flagship product, MED3000, is a topical gel specifically developed to address erectile dysfunction. The company's pipeline also encompasses a range of pain relief treatments, featuring TPR100, a topical diclofenac gel; CBD100, a topical cannabidiol preparation; and TIB200, a topical ibuprofen gel. Established in 2001, Futura Medical plc operates from its headquarters located in Guildford, United Kingdom.
5 articles
- Samsung plunges despite earnings beat, sparking fresh AI stock jitters for Nasdaq names Proactive Investors - Finance
- Futura to appeal European patent decision Proactive Investors
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.00% | +51.16% | -35.00% | -50.00% | -67.50% | -52.73% | -95.00% | -98.93% | -99.10% | -98.29% | -99.57% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
-
Revenue growth Biotechnology: +1.6%-87.8% Q4'25: -50.2% (vs Q4'23)
-
EPS growth Biotechnology: +29.7%-778.1% Q4'25: +72.8% (vs Q4'23)
-
FCF margin FCF growth · Biotechnology: +16.2%-557.5% Q4'25: -379.0% (vs Q4'23)
-
EBIT margin Biotechnology: +0.0%-528.5% Q4'25: -386.2% (vs Q4'23)
-
ROIC Biotechnology: -16.1%— Q4'25: +1,801.4% (vs Q4'23)
-
Share dilution Biotechnology: -3.4%+4.9% Q4'25: +92.1% (vs Q4'23)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×0.00× Q4'25: 0.00× (vs Q4'23)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2015 actual |
Dec 2016 actual |
Dec 2017 actual |
Dec 2018 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 1 Rev. Ana. 1 EPS Ana. |
Dec 2027 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|
| Revenue |
29.5K
est: 33.7K (-12.6%)
|
170.4K
est: 105.7K (+61.2%)
|
362.7K
est: 407.9K (-11.1%)
|
—
est: 9.5K (-100.0%)
|
3.10M
est: 3.12M (-0.7%)
|
13.93M
est: 13.90M (+0.2%)
|
1.70M
est: 1.70M (-0.2%)
|
5.08M
5.08M – 5.08M
+199.1% YoY
|
6.55M
6.55M – 6.55M
+28.8% YoY
|
| EBITDA |
-6.11M
est: 14.2K (-43,273.0%)
|
-4.55M
est: 44.3K (-10,356.9%)
|
-4.84M
est: 171.1K (-2,929.5%)
|
-7.25M
est: 4.0K (-182,313.7%)
|
-6.83M
est: 1.31M (-621.5%)
|
1.37M
est: 272.6K (+401.1%)
|
-8.84M
est: 33.3K (-26,624.2%)
|
99.7K
99.7K – 99.7K
+199.1% YoY
|
128.4K
128.4K – 128.4K
+28.8% YoY
|
| EBIT |
-6.12M
est: 14.1K (-43,503.1%)
|
-4.55M
est: 44.2K (-10,414.1%)
|
-4.86M
est: 170.4K (-2,949.2%)
|
-7.27M
est: 4.0K (-183,597.2%)
|
-6.96M
est: 1.30M (-633.6%)
|
1.24M
est: 248.3K (+401.1%)
|
-8.96M
est: 30.4K (-29,623.8%)
|
90.8K
90.8K – 90.8K
+199.1% YoY
|
117.0K
117.0K – 117.0K
+28.8% YoY
|
| Net Income |
-5.08M
est: -14.98M (+66.1%)
|
-3.70M
est: -10.09M (+63.4%)
|
-3.90M
est: -9.47M (+58.8%)
|
-5.88M
est: -12.43M (+52.7%)
|
-6.51M
est: -4.95M (-31.5%)
|
1.29M
est: 365.3K (+253.9%)
|
-9.07M
est: -3.71M (-144.7%)
|
-2.42M
-2.42M – -2.42M
+34.6% YoY
|
-729.2K
-729.2K – -729.2K
+69.9% YoY
|
| SGA |
1.37M
est: 38.1K (+3,491.0%)
|
1.21M
est: 119.4K (+917.6%)
|
1.12M
est: 460.8K (+142.7%)
|
1.23M
est: 10.7K (+11,364.9%)
|
6.69M
est: 3.53M (+89.7%)
|
6.83M
est: 26.80M (-74.5%)
|
8.47M
est: 3.28M (+158.4%)
|
9.80M
9.80M – 9.80M
+199.1% YoY
|
12.63M
12.63M – 12.63M
+28.8% YoY
|
| EPS |
-0.05
est: -0.05 (-5.8%)
|
-0.04
est: -0.03 (-11.8%)
|
-0.03
est: -0.03 (-5.4%)
|
-0.04
est: -0.04 (-11.5%)
|
-0.02
est: -0.02 (-35.6%)
|
0.00
est: 0.00 (+283.7%)
|
-0.03
est: -0.01 (-144.5%)
|
-0.01
-0.01 – -0.01
+34.6% YoY
|
0.00
0.00 – 0.00
+69.9% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-20 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-19 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-15 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-14 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-13 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-12 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-11 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-05 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-04 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-01 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-29 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-28 | C- | 1/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-21 | C- | 1/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-20 | C- | 1/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-17 | C- | 1/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Alexander James Hanbury Duggan | Chief Executive Officer & Executive Director | 623.6K | male |
| Alex Duggan | Chief Executive Officer & Executive Director | 623.6K | male |
| Angela Hildreth | Chief Operating Officer, Finance Director, Company Secretary & Executive Director | 516.0K | female |
| Kenneth William James | Head of R&D & Executive Director | 472.0K | male |
| Graham Smith | Head of Alliance Partnerships & Supply | — | — |
| Kevin Langridge | Head of Quality | — | — |
| William Duncan Potter | Chief Scientific Officer & Adviser to the Board | — | — |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for FAMDF
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
